Overview

General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

Status:
Completed
Trial end date:
2017-08-04
Target enrollment:
Participant gender:
Summary
This baseline-controlled, open-label, multicenter study evaluates the efficacy and safety of AJG555 orally administered for 2 weeks in pediatric participants with chronic constipation. The safety and efficacy of 12 weeks of administration will also be evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
EA Pharma Co., Ltd.